Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool July 31, 2009 Brian Orelli	Can Emerging Markets Save Pharma? Probably not until after they emerge.
The Motley Fool June 15, 2009 Brian Orelli	Strange Bedfellows GlaxoSmithKline is teaming up with none other than its arch-nemesis, generic-drug maker Dr. Reddy's Laboratories, licensing more than 100 of their brands to sell in emerging markets.
The Motley Fool April 15, 2011 Frank Vinluan	GSK to Shed Weight Loss Drug alli and 18 Others GSK wants to focus on fast-growing "priority brands."
The Motley Fool September 24, 2008 Brian Lawler	Sanofi Gets the Golden Ring Sanofi-Aventis raises its bid and acquires Czech generic drugmaker Zentiva.
The Motley Fool December 10, 2008 Brian Orelli	Merck: Same Plan, With a Twist With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, Merck is doing its best to replace sales by pushing new drugs through its pipeline.
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
Chemistry World May 21, 2009 Matt Wilkinson	Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets.
Chemistry World January 11, 2013 Andrew Turley	Pharma industry 'strategic crisis' The pharma industry is grappling with a 'strategic crisis' according to three quarters of companies surveyed in a report from consultancy firm Roland Berger.
The Motley Fool January 19, 2011 Cliff D'Arcy	Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements.
Pharmaceutical Executive September 1, 2008 Sarah Houlton	Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units.
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool May 11, 2010 Brian Orelli	Abbott Makes a Push Into Selling Leftovers Abbott Labs has jumped on the established-product-division bandwagon. The company has licensed 24 products from Zydus Cadila of India and has the option to market another 40.
BusinessWeek April 15, 2010 Kanoko Matsuyama	Looking East, Big Pharma Cuts Prices Drugmakers are beginning to choose sales volume over high margins to tap the massive Asian market
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
The Motley Fool October 26, 2006 Brian Lawler	Glaxo's Prescription for Sagging Sales Trading at roughly 32 times its trailing-12-month earnings, and with a solid 2.9% dividend yield, GSK is a fine investment for shareholders patient enough to wait until 2008 for a return to solid revenue growth.
The Motley Fool September 28, 2007 Brian Lawler	GSK Helps Secure Future of a Lead Drug GlaxoSmithKline settles a patent infringement case on a lead drug, Avandia, and with that challenger gone, the company is a step closer to securing one of its top franchises.
The Motley Fool January 26, 2009 Brian Orelli	Have Drugs, Will Travel After buying Bristol-Myers Squibb's businesses in Egypt and Pakistan, GlaxoSmithKline is now off to Africa.
Chemistry World July 29, 2013 Hepeng Jia	China corruption investigation broadens Investigations of corrupt practices at GlaxoSmithKline in China are continuing. But analysts claim that the scandal is an attempt to remodel the Chinese drugs market, rather than a deliberate attack on international companies.
The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
Chemistry World June 5, 2009 Anna Lewcock	Pharma's new world order So-called 'pharmerging' markets will contribute over half of the growth of the global pharmaceutical market this year, according to market analysts.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool September 15, 2011 Frank Vinluan	GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago.
The Motley Fool April 12, 2011 Brian Orelli	Merck Joins the Low-Margin Party The American drugmaker announces that it is partnering with Sun Pharma to establish a joint venture to sell branded generics in emerging markets.
The Motley Fool August 4, 2011 Frank Vinluan	Skin in the Game: How Acne Skin Care Fits GSK's Drug Portfolio Strategy GSK thinks long-term with this acne skin care product.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
Chemistry World July 25, 2008 Sarah Houlton	Small is beautiful for GSK drug discovery New GlaxoSmithKline chief executive Andrew Witty is restructuring the firm's drug discovery, setting up small, highly focussed research teams that will have to bid for funding.
BusinessWeek October 4, 2004 Kerry Capell	Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving.
The Motley Fool October 25, 2007 Brian Lawler	Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
Chemistry World April 20, 2009 Phil Taylor	GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'.
The Motley Fool July 26, 2011 Cliff D'Arcy	GSK Showers Shareholders With Cash GlaxoSmithKline, the U.K.'s largest pharmaceutical company, has released its second-quarter results. Thanks to rising earnings and dividends, its shares remain attractively priced, particularly to income-seeking investors.
Chemistry World May 19, 2015 Phillip Broadwith	GSK commits to HIV research GlaxoSmithKline has reaffirmed its commitment to researching new drugs for HIV -- Aids, by partnering with the University of North Carolina in Chapel Hill, US.
The Motley Fool November 3, 2011 Frank Vinluan	GSK Settles With Uncle Sam for $3B GSK said the settlement will reduce financial uncertainty for the company and is in the best interest of shareholders.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
The Motley Fool June 14, 2007 Brian Lawler	Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool October 8, 2008 Brian Orelli	Pfizer Rearranges the Deck Chairs A reorganization without any job cuts isn't going to make the Lipitor problem go away.
Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
Pharmaceutical Executive August 1, 2011 Ben Comer	Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
The Motley Fool September 11, 2008 Brian Lawler	Will a Change Cure Sanofi? The drugmaker charts a different course for its future.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool October 28, 2009 Brian Orelli	Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
Chemistry World December 5, 2014 Andy Extance	GSK cuts US jobs in push for savings 350 of the chemists, engineers and other roles will be lost by April 2015, another 450 by July, and the remainder eliminated by the end of the year.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.